A study combining a tetravalent bispecific antibody targeting HER2 (Erb2) and NKGD2 with NKG2D-based CARs (NKAR) showed impressive suppression of tumor growth in a murine model of GBM with low expression of NKG2D-L [79]. This evidence concerns the gene ERBB2 and glioblastoma.